Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash.
August 2, 2025
by ACN Newswire
RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer
At 2025 ASCO GU, Prof. Xinan Sheng disclosed phase II trial data of DV + Toripalimab for HER2 - expressing MIBC, showing high pCR and manageable safety.
February 15, 2025
by PR Newswire
The Landscape of Biomarkers: From Traditional Measures to Multi-Omics Powerhouses
A biomarker is an indicator that can be quantified to show whether a biological process is pathogenic, normal, or responding to an intervention or exposure.
February 18, 2024
by Shruti Talshi
Breakthroughs in Melanoma Immunotherapy & RNA Vaccines
Melanoma is a type of skin cancer that develops from pigment-producing cells called melanocytes.
July 3, 2023
by Daivd Orchard Webb/PharmaSources
Malaysian Genomics Pivots to Biopharmaceuticals for Growth
Group reports lower revenue for 2Q on switch to immunotherapy and cell therapies from vaccines
March 7, 2023
by PharmaSources
Antihistamines can influence immunotherapy response by enhancing T cell activation
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors.
November 29, 2021
by FirstWordPharma
Creative Medical Technology Holdings Announces $3.8 Million Private Placement with Institutional Investors
Creative Medical Technology Holdings, Inc. ("CELZ," the "Company", "we", "our" or "us") (OTC: CELZ) today announced that it has entered into definitive agreements with accredited institutional investors for gross proceeds of approximately $3,788,000.
August 10, 2021
by firstwordpharma
New breakthrough to help immune systems in the fight against cancer
New research has identified potential treatment that could improve the human immune system's ability to search out and destroy cancer cells within the body.
July 28, 2021
by prnewswire
Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases
Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, today announced the closing of a $63 million Series B financing.
July 28, 2021
by firstwordpharma
OncoSec Appoints Brian Leuthner as Interim CEO
OncoSec Medical Incorporated (NASDAQ:ONCS) today announced that Daniel O'Connor has resigned and that Brian Leuthner, formerly Chief Operating Officer, has been appointed Interim Chief Executive Officer, effective June 25, 2021.
June 25, 2021
by firstwordpharma
Werewolf Therapeutics Appoints Mike Sherman to its Board of Directors
Werewolf Therapeutics, Inc. today announced the appointment of Mike Sherman, chief executive officer of Chimerix, Inc., as a member of its board of directors.
May 31, 2021
by firstwordpharma
A Glimpse of the Oncology Drug Treatment Market in China
According to statistics, the market size of China’s oncology treatment industry reached RMB387.6 billion in 2020, with a compound annual growth rate of 10.3% in the past five years as compared to RMB261.4 billion in 2016, and this market size is expected
May 31, 2021
by PharmaSources/Xiaoyaowan